Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue - Narrative (Details)

Revenue - Narrative (Details) $ / shares in Units, € in Millions														1 Months Ended								3 Months Ended		12 Months Ended
	Mar. 29, 2021 USD ($) $ / shares shares	Mar. 24, 2021 USD ($) $ / shares shares	Feb. 08, 2018 USD ($) program researchProgram performanceObligation swapOption license	May 02, 2017 performanceObligation	May 02, 2017 USD ($) performanceObligation	May 02, 2017 performanceObligation researchProgram	May 02, 2017 performanceObligation license	May 02, 2017 performanceObligation	May 02, 2017 performanceObligation protein	May 02, 2017 leaseAgreement performanceObligation	Feb. 27, 2017 USD ($)	Jan. 04, 2017 USD ($) performanceObligation preclinicalMilestone protein bispecificTherapeuticProgram license extensionOption collaborationProduct	Jan. 04, 2017 EUR (€) performanceObligation preclinicalMilestone protein bispecificTherapeuticProgram license extensionOption collaborationProduct	Mar. 31, 2021 USD ($)	Feb. 28, 2021	Feb. 29, 2020 collaborationProduct program	Nov. 30, 2019 USD ($) $ / shares shares	Feb. 28, 2019 USD ($)	Feb. 28, 2019 EUR (€)	Dec. 31, 2018 USD ($) preclinicalMilestone	Dec. 31, 2018 EUR (€) preclinicalMilestone	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jan. 01, 2019 USD ($)	May 02, 2017 collaborationProduct
Disaggregation of Revenue [Line Items]
Revenue recognized from contract with customer																								$ 15,000,000.0
Revenues																								29,323,000	$ 46,279,000
Deferred revenues, current portion																								12,627,000	11,256,000
Deferred revenue, net of current portion																								35,900,000	47,258,000
Number of technology licenses (in licenses) \| leaseAgreement										5
Number of separate performance obligations (in performance obligations) \| performanceObligation												1	1
Additions to contract with customer, liability																								1,600,000
Private Placement
Disaggregation of Revenue [Line Items]
Shares of common stock issued (shares) \| shares																	9,014,960
Net proceeds from private placement																	$ 31,000,000.0
Issue price per share (USD per share) \| $ / shares																	$ 3.55
Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations (in performance obligations) \| performanceObligation			3
Remaining performance obligation																								20,700,000
Revenues																								9,702,000	2,493,000
Deferred revenues, current portion																								5,700,000
Deferred revenue, net of current portion																								11,800,000
Seagen \| Subsequent Event \| Private Placement
Disaggregation of Revenue [Line Items]
Shares of common stock issued (shares) \| shares		3,706,174
Net proceeds from private placement		$ 13,000,000.0												$ 13,000,000.0
Issue price per share (USD per share) \| $ / shares		$ 3.51
AstraZeneca
Disaggregation of Revenue [Line Items]
Remaining performance obligation																								25,400,000
Revenues																								8,308,000	25,828,000
Deferred revenues, current portion																								900,000
Deferred revenue, net of current portion																								18,600,000
Research collaboration agreement term				5 years
AstraZeneca \| Subsequent Event
Disaggregation of Revenue [Line Items]
Revenues														13,000,000.0
AstraZeneca \| Subsequent Event \| Private Placement
Disaggregation of Revenue [Line Items]
Shares of common stock issued (shares) \| shares	3,584,230
Net proceeds from private placement	$ 10,000,000.0													$ 10,000,000.0
Issue price per share (USD per share) \| $ / shares	$ 2.79
Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of performance obligations (in performance obligations) \| performanceObligation												10	10
Remaining performance obligation																								11,600,000
Revenue recognized from contract with customer																							$ 7,100,000
Revenues																								11,313,000	$ 15,048,000
Research term extension period																12 months
Number of preclinical stage programs (in programs) \| program																2
Period to complete remaining obligations on programs																60 days
Deferred revenues, current portion																								6,000,000.0
Deferred revenue, net of current portion																								5,500,000
Number of novel proteins (in proteins) \| protein												1	1
Number of research programs (in research programs) \| program																5
Capitalized contract cost, net																								200,000
Amortization of capitalized contract costs																								100,000
Number of research programs \| bispecificTherapeuticProgram												3	3
Number of separate performance obligations (in performance obligations) \| performanceObligation												2	2
Number of combined performance obligations (in obligations) \| performanceObligation												2	2
Les Laboratoires Servier and Institut de Recherches Internationales Servier \| Subsequent Event
Disaggregation of Revenue [Line Items]
Research term extension period															12 months
Les Laboratoires Servier and Institut de Recherches Internationales Servier \| Research and development services
Disaggregation of Revenue [Line Items]
Research collaboration agreement term												3 years	3 years
Number of preclinical milestones (in preclinical milestones) \| preclinicalMilestone												2	2							1	1
ASKA Pharmaceutical Co. Ltd.
Disaggregation of Revenue [Line Items]
Revenue recognized from contract with customer																								0
Capitalized contract cost, net											$ 300,000
Evaluation period											60 days
Upfront option payment received											$ 2,750,000
License and collaboration agreement \| Seagen
Disaggregation of Revenue [Line Items]
Number of research programs (in research programs) \| researchProgram			3
Period after effective date agreements may be terminated			12 months
Contract termination advance notice period			90 days
Agreement termination advance notice period if marketing approval obtained			180 days
Agreement termination notice period upon material breach by the Company			90 days
Contract termination due to material breach, additional notice period if the breach is not susceptible			90 days
Number of licenses (in licenses) \| license			3
Number of swap options (in swap options) \| swapOption			2
Number of performance obligations (in performance obligations) \| performanceObligation			6
License and collaboration agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Period after effective date agreements may be terminated				12 months
Contract termination advance notice period				90 days
Agreement termination advance notice period if marketing approval obtained				180 days
Agreement termination notice period upon material breach by the Company				180 days
Contract termination due to material breach, additional notice period if the breach is not susceptible				180 days
Number of performance obligations (in performance obligations) \| performanceObligation								16
Number of novel proteins (in proteins) \| protein									4
Agreement termination notice period upon breach of payment obligations by the Company				30 days
Period of license performance obligation				12 months
License and collaboration agreement \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of licenses (in licenses) \| license												5	5
Number of performance obligations (in performance obligations) \| performanceObligation												4	4
Number of collaboration products (in collaboration products) \| collaborationProduct												2	2
Number of research programs (in research programs) \| bispecificTherapeuticProgram												5	5
Number of research programs \| bispecificTherapeuticProgram												5	5
Collaborative arrangement \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Period after effective date agreements may be terminated												12 months	12 months
Contract termination advance notice period												180 days	180 days
Revenue recognized from contract with customer																		$ 1,700,000	€ 1.5	$ 600,000	€ 0.5
Number of research and development licenses (in licenses) \| license												4	4
Co-development collaboration product \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products) \| collaborationProduct																1
Servier developed collaboration product \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products) \| collaborationProduct																1
Other arrangement \| Seagen
Disaggregation of Revenue [Line Items]
Number of research programs (in research programs) \| researchProgram			2
Platform technology license \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations (in performance obligations) \| performanceObligation			3
Number of target programs (in programs) \| program			3
Antibody target swap \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations (in performance obligations) \| performanceObligation			2
Governance committee participation \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations (in performance obligations) \| performanceObligation			1
Upfront payment \| Seagen
Disaggregation of Revenue [Line Items]
Research and development services			$ 4,900,000
Deferred revenue			1,200,000,000
Upfront payment \| Seagen \| License fees
Disaggregation of Revenue [Line Items]
Revenue			$ 30,000,000.0
Upfront payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration					$ 45,000,000.0
Upfront payment \| Les Laboratoires Servier and Institut de Recherches Internationales Servier \| License fees
Disaggregation of Revenue [Line Items]
Revenue												$ 32,000,000.0	€ 30.0
Additional other research services \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration					4,700,000
Estimated development and manufacturing services \| Upfront payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration					14,200,000
Milestone payments \| Upfront payment \| Seagen
Disaggregation of Revenue [Line Items]
Revenue recognized from contract with customer																								4,200,000
Allocable arrangement consideration																						$ 5,000,000.0
Milestone payments \| Upfront payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration					12,500,000
Estimated phase 2a services \| Upfront payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration					$ 4,700,000
Agreement extension options \| Les Laboratoires Servier and Institut de Recherches Internationales Servier \| Research and development services
Disaggregation of Revenue [Line Items]
Research collaboration agreement term												1 year	1 year
Number of agreement extension options (extension options) \| extensionOption												2	2
Minimum \| License and collaboration agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products) \| collaborationProduct																											2
Minimum \| Collaborative arrangement \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Agreement termination notice period upon material breach by the Company												90 days	90 days
Maximum \| License and collaboration agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products)				4	4	4	4	4	4	4																	4
Number of research programs (in research programs) \| researchProgram						2
Number of research licenses (in licenses)							4			4
Maximum \| Collaborative arrangement \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Agreement termination notice period upon material breach by the Company												120 days	120 days
Accounting Standards Update 2014-09 \| AstraZeneca
Disaggregation of Revenue [Line Items]
Capitalized contract cost, net																								$ 700,000		$ 1,600,000
Capitalized contract cost in accordance with ASC 340																										1,100,000
Accounting Standards Update 2014-09 \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Capitalized contract cost, net																										$ 500,000